ATE377000T1 - 5-ht1f agonisten - Google Patents
5-ht1f agonistenInfo
- Publication number
- ATE377000T1 ATE377000T1 AT00915719T AT00915719T ATE377000T1 AT E377000 T1 ATE377000 T1 AT E377000T1 AT 00915719 T AT00915719 T AT 00915719T AT 00915719 T AT00915719 T AT 00915719T AT E377000 T1 ATE377000 T1 AT E377000T1
- Authority
- AT
- Austria
- Prior art keywords
- ht1f agonists
- ht1f
- agonists
- mammal
- activating
- Prior art date
Links
- 102100036311 5-hydroxytryptamine receptor 1F Human genes 0.000 title 1
- 101710138086 5-hydroxytryptamine receptor 1F Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 206010015866 Extravasation Diseases 0.000 abstract 1
- 101000941893 Felis catus Leucine-rich repeat and calponin homology domain-containing protein 1 Proteins 0.000 abstract 1
- 101150039275 Htr1f gene Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000036251 extravasation Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11959699P | 1999-02-10 | 1999-02-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE377000T1 true ATE377000T1 (de) | 2007-11-15 |
Family
ID=22385241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00915719T ATE377000T1 (de) | 1999-02-10 | 2000-02-09 | 5-ht1f agonisten |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1153013B1 (de) |
| JP (1) | JP2002536434A (de) |
| KR (1) | KR20010102003A (de) |
| CN (1) | CN1149195C (de) |
| AT (1) | ATE377000T1 (de) |
| AU (1) | AU770098B2 (de) |
| BR (1) | BR0008112A (de) |
| CA (1) | CA2360164A1 (de) |
| DE (1) | DE60036924T2 (de) |
| ES (1) | ES2295017T3 (de) |
| WO (1) | WO2000047559A2 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0302582A2 (hu) * | 2000-12-22 | 2003-12-29 | Schering Corp. | Piperidin MCH antagonisták, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk elhízás kezelésére |
| TWI263497B (en) * | 2002-03-29 | 2006-10-11 | Lilly Co Eli | Pyridinoylpiperidines as 5-HT1F agonists |
| JP2006523692A (ja) | 2003-04-18 | 2006-10-19 | イーライ リリー アンド カンパニー | ５−ｈｔ１ｆ作用薬としての（ピペリジニルオキシ）フェニル、（ピペリジニルオキシ）ピリジニル、（ピペリジニルスルファニル）フェニル、および（ピペリジニルスルファニル）ピリジニル化合物 |
| UA82711C2 (en) * | 2003-09-12 | 2008-05-12 | Эли Лилли Энд Компани | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists |
| EP1697305B1 (de) | 2003-12-17 | 2007-08-15 | Eli Lilly And Company | Substituierte (4-aminocyclohexen-1-yl) phenyl and (4-aminocyclohexen-1-yl) pyridinyl verbindungen als 5-ht1f agonisten |
| US20080021034A1 (en) * | 2006-04-10 | 2008-01-24 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
| TW200914020A (en) * | 2007-08-28 | 2009-04-01 | Lilly Co Eli | Substituted piperazinyl pyrazines and pyridines as 5-HT7 receptor antagonists |
| JP5727457B2 (ja) | 2009-04-02 | 2015-06-03 | コルーシッド ファーマシューティカルズ， インコーポレイテッド | ２，４，６−トリフルオロ−ｎ−［６−（１−メチル−ピペリジン−４−カルボニル）−ピリジン−２−イル］−ベンズアミドの組成物 |
| US8697876B2 (en) | 2010-04-02 | 2014-04-15 | Colucid Pharmaceuticals, Inc. | Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists |
| WO2016027757A1 (ja) * | 2014-08-18 | 2016-02-25 | 国立大学法人大阪大学 | 新規２－アミノベンゾイル誘導体 |
| TWI826514B (zh) | 2018-09-04 | 2023-12-21 | 美商美國禮來大藥廠 | 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥 |
| AR119319A1 (es) | 2019-07-09 | 2021-12-09 | Lilly Co Eli | Procesos e intermediario para la preparación a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida y preparación de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida |
| CN110981854B (zh) * | 2019-09-10 | 2023-03-28 | 南京三元阳普医药科技有限公司 | 2-氨基-6-(1-烷基哌啶-4-羰基)吡啶类化合物的合成方法 |
| CN110845402B (zh) * | 2019-11-22 | 2023-05-09 | 广东东阳光药业有限公司 | 吡啶亚甲基哌嗪衍生物及其用途 |
| CN111187252B (zh) * | 2019-11-22 | 2023-06-09 | 广东东阳光药业有限公司 | 吡啶酰基氮杂螺庚烷衍生物及其用途 |
| CN111187251B (zh) * | 2019-11-22 | 2023-06-09 | 广东东阳光药业有限公司 | 吡啶酰基哌啶衍生物及其用途 |
| CN111004214B (zh) * | 2019-11-22 | 2021-06-08 | 广东东阳光药业有限公司 | 吡啶酰基哌啶衍生物及其用途 |
| WO2021097781A1 (zh) * | 2019-11-22 | 2021-05-27 | 广东东阳光药业有限公司 | 吡啶亚甲基哌啶衍生物及其用途 |
| CN114573555B (zh) * | 2020-11-30 | 2026-02-17 | 上海天慈国际药业有限公司 | 一种用于治疗偏头痛的化合物的制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7177694A (en) * | 1993-06-23 | 1995-01-17 | Cambridge Neuroscience, Inc. | Sigma receptor ligands and the use thereof |
| KR19980703048A (ko) * | 1995-03-20 | 1998-09-05 | 피터쥐.스트링거 | 5-치환-3-(1,2,3,6-테트라히드로피리딘-4-일)- 및 3-(피페리딘-4-일)-1ｈ-인돌: 신규한 5-ｈｔ1ｆ 아고니스트 |
| AU4074897A (en) * | 1996-09-18 | 1998-04-14 | Eli Lilly And Company | A method for the prevention of migraine |
-
2000
- 2000-02-09 CA CA002360164A patent/CA2360164A1/en not_active Abandoned
- 2000-02-09 DE DE60036924T patent/DE60036924T2/de not_active Expired - Fee Related
- 2000-02-09 EP EP00915719A patent/EP1153013B1/de not_active Expired - Lifetime
- 2000-02-09 BR BR0008112-4A patent/BR0008112A/pt not_active IP Right Cessation
- 2000-02-09 AU AU36945/00A patent/AU770098B2/en not_active Ceased
- 2000-02-09 KR KR1020017010048A patent/KR20010102003A/ko not_active Withdrawn
- 2000-02-09 WO PCT/US2000/002502 patent/WO2000047559A2/en not_active Ceased
- 2000-02-09 CN CNB008035768A patent/CN1149195C/zh not_active Expired - Fee Related
- 2000-02-09 ES ES00915719T patent/ES2295017T3/es not_active Expired - Lifetime
- 2000-02-09 JP JP2000598480A patent/JP2002536434A/ja not_active Withdrawn
- 2000-02-09 AT AT00915719T patent/ATE377000T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE60036924T2 (de) | 2008-08-14 |
| AU770098B2 (en) | 2004-02-12 |
| DE60036924D1 (de) | 2007-12-13 |
| WO2000047559A2 (en) | 2000-08-17 |
| CN1340045A (zh) | 2002-03-13 |
| EP1153013A2 (de) | 2001-11-14 |
| KR20010102003A (ko) | 2001-11-15 |
| CN1149195C (zh) | 2004-05-12 |
| JP2002536434A (ja) | 2002-10-29 |
| CA2360164A1 (en) | 2000-08-17 |
| AU3694500A (en) | 2000-08-29 |
| EP1153013B1 (de) | 2007-10-31 |
| ES2295017T3 (es) | 2008-04-16 |
| WO2000047559A3 (en) | 2000-11-30 |
| BR0008112A (pt) | 2001-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69912279D1 (de) | 5-ht1f agonisten | |
| DE60036924D1 (de) | 5-ht1f agonisten | |
| WO2000006173A8 (en) | 5-ht1f agonists | |
| EA200100203A1 (ru) | Производные 4,4-биарилпиперидина с активностью в отношении опиоидных рецепторов | |
| MXPA04000328A (es) | Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer. | |
| BR0111596A (pt) | Composto e seu uso, processo para sua produção, composição farmacêutica e processo e método para prevenir ou tratar doenças | |
| DK0850221T3 (da) | Meta-guanidin-, urinstof-, thiourinstof- eller azacykliske aminobenzoesyrederivater som intergrinantagonister | |
| BG106867A (en) | Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory autoimmune and respiratory diseases | |
| BRPI0409624A (pt) | 2-hidróxi-3-diaminoalcanos de benzamida | |
| WO2000000490A3 (en) | 5-ht1f agonists | |
| BR0111377A (pt) | Derivados de tiofeno úteis como agentes anticancerìgenos | |
| MXPA04002785A (es) | Aminas sustituidas para tratamiento de enfermedad de alzheimer. | |
| BRPI0409627A (pt) | 2-hidróxi-3-diaminoalcanos de fenacila | |
| NO20003018D0 (no) | Triazinangiogenese-inhibitorer | |
| PE20011085A1 (es) | Compuestos isoxazolquinolin o imidazolquinolin como inhibidores de la proteina resistente a multifarmacos | |
| NO985518L (no) | Morfinanderivater og medisinsk anvendelse derav | |
| TNSN04138A1 (fr) | Metabolites de l'acide (3-{[4-tertiobutylbenzyl)-(pyridine-3-sulfonyl)-amino] - methyl}-phenoxy)-acetique | |
| NO20014127L (no) | 5-HT1F agonister | |
| NO20010940L (no) | TAN-1057 derivater | |
| TNSN99146A1 (fr) | Derives de 1-heteroaryl-pyrrolidine, -piperidine et - homopiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TR200103562T2 (tr) | Amiloid proteini toplanmasını önleme ve amiloid birikintilerini görüntüleme yönteminde kullanım için rodanin türevleri | |
| ATE308513T1 (de) | Naphthamid-neurokinin antagonisten zur verwendung als medikamente | |
| UY27570A1 (es) | Sal de ácido cítrico de un compuesto terapéutico y composiciones farmacéuticas que la contienen | |
| FR2835253B1 (fr) | Composes, en particulier de derives urees ou esters de l'acide haloacetamidobenzoique et leur utilisation pour le traitement de maladies parasitaires | |
| US6541495B1 (en) | Carboxylic acid derivatives as inhibitors of hyperproliferation diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |